期刊文献+

原发于盆腔淋巴结的淋巴管肌瘤病临床病理特征探讨 被引量:1

Clinicopathological features of primary lymphangioleiomyomatosis in pelvic lymph nodes
下载PDF
导出
摘要 目的探讨淋巴管肌瘤病的临床病理特点、诊断及治疗方法。方法报道1例原发于盆腔淋巴结的淋巴管肌瘤的临床资料、光镜及免疫组织化学结果,并结合文献讨论。结果组织学显示右髂内和左腹股沟淋巴结内平滑肌样细胞增生并呈束状排列,伴脂肪化生。增生的细胞形态善良,某些具有上皮样细胞特点,含丰富的嗜酸性胞浆,分裂象罕见。免疫组织化学:增生的细胞SMA(弥漫+),HMB-45(灶性+),CK(AE1/AE3)(-);内衬淋巴管内皮细胞D2-40(+),CD34(-)。结论原发盆腔淋巴结的肺外淋巴管肌瘤比较罕见,免疫组织化学对诊断有重要意义。手术切除后一般预后良好。 Objective To investigate the clinical pathologic characteristics ,diagnosis and treatment methods of lymphangioleio‐myomatosis(LAM ) .Methods The clinical data ,light microscopic and immunohistochemical results in 1 case of LAM originated from pelvic lymph nodes were reported and discussed by combining with the related literatures .Results The histology revealed that the right internal iliac and left inguinal lymph nodes had hyperplasia of smooth muscle‐like cells and which arranged in bundles accompanied by fat metaplasia .The hyperplastic cells had good morphology ,some cells had the epithelioid cell feature and contained abundant acidophilic cytoplasm .The karyokinesis figure was rare .The immunohistochemical results showed that the hyperplastic cells were positive for SMA and HMB45 ,but negative for CK(AE1/AE3) ;inner lining lymphatic endothelial cells D2‐40 were posi‐tive ,but CD34 was negative .Conclusion Primary pelvic lymph node LAM is relatively rare .Immunohistochemistry has an impor‐tant significance for its diagnosis .The general prognosis is good after surgical excision .
出处 《检验医学与临床》 CAS 2016年第18期2616-2618,共3页 Laboratory Medicine and Clinic
关键词 淋巴管肌瘤病 盆腔淋巴结 诊断 lymphangioleiomyomatosis pelvic lymph node diagnosis
  • 相关文献

参考文献16

  • 1Johnson SR,Cordier JF, Lazor R, et al. European respira- tory society guidelines for the diagnosis and management of lymphangioleiomyomatosis [J ]. Eur Respir J, 2010, 35 (1) :14-26.
  • 2Ryu JH, Moss J,Beck GJ, et al. The NHLBI lymphangio- leiomyomatosis registry:characteristics of 230 patients at enrollment[J]. Am J Respir Crit Care Med, 2006,173 (1) :105-111.
  • 3Muzykewicz DA, Sharma A, Muse V, et al. TSC1 and TSC2 mutations in patients with lymphangioleiomyoma- tosis and tuberous sclerosis complex[J]. J Med Genet, 2009,46 (7) : 465-468.
  • 4Krymskaya VP. Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis [J]. Proc Am Thorac Soc, 2008,5(1) : 119-126.
  • 5Goncharova EA, Krymskaya VP. Pulmonary lymphangio- leiomyomatosis (LAM):progress and current challenges [J]. J Cell Biochem,2008,103(2) :369-382.
  • 6Gu X,Yu JJ,Ilter D,et al. Integration of mTOR and es- trogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis[J]. Proc Natl Acad Sci U S A, 2013, 110 (37) : 14960-14965.
  • 7Lee PS, Tsang SW, Moses MA, et al. Rapamycin-Insensi- tive Up-Regulation of MMP2 and other genes in tuberous sclerosis complex 2-Deficient Lymphangioleiomyomatosis- Like cells[J]. Am J Respir Cell Mol Biol, 2010,42(2): 227-234.
  • 8周婧,杨树东,陈文凯,蔡颖,梁家贝,吴广斌,杨国仪.肺淋巴管平滑肌瘤病中β-catenin的表达及鉴别诊断意义[J].诊断病理学杂志,2015,22(1):23-26. 被引量:5
  • 9Grzegorek I, Lenze D, Chabowski M, et al. Immunohisto- chemical evaluation of pulmonary lymphangioleiomyoma- tosis[J]. Anticancer Res, 2015,35 (6) : 3353-3360.
  • 10Valencia JC, Steagall WK, Zhang Y, et al. Antibody aPEP13h reacts with lymphangioleiomyomatosis cells in lung nodules[J]. Chest,2015,147(3) :771-777.

二级参考文献11

共引文献4

同被引文献4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部